Clinical Effect of Fondaparinux Combined with Rrivaroxaban in Preventing DVT of Lower Limbs after Major Orthopedic Surgery
Objective To explore the clinical effect of fondaparinux combined with rivaroxaban in preventing deep vein thrombosis (DVT) of lower limbs after major orthopaedic surgery. Methods A total of 116 patients with major orthopaedic surgery treated in Heze Hospital of Traditional Chinese Medicine from December 2021 to December 2022 were selected as the research objects. They were divided into a control group and an experimental group according to random number table method,with 58 cases in each group. The control group was treated with rivaroxaban,and the experimental group was treated with fondaparinux combined with rivaroxaban. The incidence of DVT,coagulation index,inflammation index,blood cell index and adverse reactions were compared between the two groups. Results The incidence of DVT in observation group was lower than that in control group,the difference was statistically significant (P<0.05). After treatment,the levels of fibrinogen (FIB) and D-dimer (D-D) in observation group were lower than those in control group,and the differences between groups were statistically significant (P<0.05). There were no significant differences in thrombin time,C-reactive protein level,white blood cell count,platelet count and hemoglobin level between the two groups before and after treatment (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The combination of sulfodaparine and rivaroxaban can reduce the incidence of DVT in lower limbs after major orthopedic surgery,regulate FIB and D-D levels,and have no significant effects on inflammation and blood cell indexes,so it has a high safety.
Major orthopaedic surgeryFondaparinuxRivaroxabanDeep vein thrombosis of lower limbs
NETL
NSTL
万方数据
